International Journal of Endocrinology最新文献

{"title":"The Mediating Role of Body Mass Index in the Association of Socioeconomic Status With Hepatic Steatosis and Liver Fibrosis: A Cross-Sectional Study Based on NHANES 2021-2023.","authors":"Zongnan Chen, Xiaoling Zhu, Juan Guo, Gang Ma","doi":"10.1155/ije/4478977","DOIUrl":"10.1155/ije/4478977","url":null,"abstract":"<p><p><b>Background:</b> Socioeconomic status (SES) influences a wide range of health outcomes, including hepatic steatosis and liver fibrosis, which are increasingly concerning. The aim of the study was to investigate the association between SES and hepatic steatosis and liver fibrosis and examine the potential mediating effects of body mass index (BMI) in this association. <b>Methods:</b> We used the National Health and Nutrition Examination Survey (NHANES) 2021-2023 data to conduct a cross-sectional study. Occupation, insurance, family income level, and education level were employed as indicators of SES. Hepatic steatosis and liver fibrosis were quantified by controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), respectively. Mediation analysis was used to estimate the direct and indirect associations of SES with hepatic steatosis and liver fibrosis through BMI after adjustment for potential confounders. <b>Results:</b> The study included 4455 participants. Compared to individuals with low SES, those with high SES had a lower risk of hepatic steatosis (odds ratios [OR] = 0.80, 95% CI: 0.69-0.94, <i>p</i> < 0.01) and liver fibrosis (OR = 0.77, 95% CI: 0.61-0.97, <i>p</i>=0.03). However, after adjusting for confounding factors, the associations were no longer statistically significant (hepatic steatosis: OR = 0.90, 95% CI: 0.75-1.08, <i>p</i>=0.25; liver fibrosis: OR = 0.87, 95% CI: 0.67-1.15, <i>p</i>=0.32). BMI differed significantly across SES grades (<i>p</i>=0.04). Restricted cubic spline analysis revealed a significant nonlinear positive association between BMI and hepatic steatosis (<i>p</i> < 0.01), and a linear positive association with liver fibrosis (<i>p</i>=0.11). Moreover, BMI accounted for 32.8% of the mediation effect between SES and hepatic steatosis and 18.2% of the mediation effect between SES and liver fibrosis. <b>Conclusion:</b> People with higher SES are less likely to develop hepatic steatosis and liver fibrosis, although the associations were attenuated after adjustment for confounding factors. SES might contribute to hepatic steatosis and liver fibrosis through the involvement of BMI.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"4478977"},"PeriodicalIF":2.3,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12440650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145080634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uncovering Overlapping Gene Networks and Potential Therapeutic Targets in Osteoporosis and COVID-19 Through Bioinformatics Analysis.","authors":"Yuwen Luo, Shizhen Liu, Xianyin Liu, Shu Zhong, Ye Wang, Zheng Wan","doi":"10.1155/ije/8816596","DOIUrl":"10.1155/ije/8816596","url":null,"abstract":"<p><p><b>Background:</b> Osteoporosis is a progressive bone disease characterized by reduced bone density and deterioration of bone microarchitecture, predominantly affecting the elderly population. The ongoing COVID-19 pandemic has introduced additional challenges in osteoporosis management, potentially due to systemic inflammation and direct viral impacts on bone metabolism. This study aims to identify common differentially expressed genes (DEGs) and key molecular pathways shared between osteoporosis and COVID-19, with the goal of uncovering potential therapeutic targets through bioinformatics analysis. <b>Methods:</b> Publicly available gene expression datasets GSE164805 (osteoporosis) and GSE230665 (COVID-19) were analyzed to identify overlapping DEGs. Functional enrichment analysis using Gene Ontology (GO), pathway analysis, protein-protein interaction (PPI) network construction, and transcription factor (TF)-hub gene regulatory network analysis were performed to explore the biological significance and regulatory mechanisms of these DEGs. <b>Results:</b> A total of 325 common DEGs were identified between osteoporosis and COVID-19. GO enrichment analysis revealed significant involvement in signal transduction and plasma membrane components. Pathway analysis highlighted the \"cytokine-cytokine receptor interaction\" pathway as a central player. PPI network analysis identified a module of 193 genes with 397 interactions, from which 10 key hub genes were prioritized: ACTB, CDH1, RPS8, IFNG, RPL17, UBC, RPL36, RPS4Y1, GSK3B, and FGF13. Furthermore, 76 TFs were found to regulate these hub genes, and 15 existing drugs targeting four of these hub genes were identified. <b>Conclusion:</b> This integrative bioinformatics study reveals 15 candidate therapeutic agents that target key regulatory genes shared between osteoporosis and COVID-19, offering promising treatment strategies for osteoporotic patients, especially those impacted by or at risk of SARS-CoV-2 infection.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"8816596"},"PeriodicalIF":2.3,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145015159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Causal Mechanism Between the Dipeptidyl Peptidase-4, Heart Failure, and Other Cardiovascular Diseases: A Mendelian Randomization and Mediation Study.","authors":"Che-Kai Chen, Chang-Fu Kuo, Yu-Jing Chang, Weiya Zhang, Michael Doherty, Ming-Ling Chang, Tsung-Hsing Chen","doi":"10.1155/ije/2357272","DOIUrl":"10.1155/ije/2357272","url":null,"abstract":"<p><p><b>Aims:</b> Dipeptidyl peptidase-4 (DPP4) inhibitors are commonly used to treat type 2 diabetes. However, the causality of it on cardiovascular diseases (CVDs) is controversial. This study aimed (1) to investigate the causal mechanisms of DPP4 gene expression at the mRNA level on CVDs, including all-cause heart failure (HF), atrial fibrillation (AF), myocardial infarction (MI), and stroke in a European population; (2) to assess the direct effect of DPP4 at the mRNA level on CVD, which is independent of type-2 diabetes; and (3) to explore the causality of DPP4 inhibition on CVDs and type-2 diabetes. <b>Methods:</b> Utilizing DPP4 and CVD summary statistics from eQTLGen Consortium, GTEx Portal, and UK Biobank, we applied weak IV and pleiotropy robust Mendelian randomization methods (MR-RAPS, GRAPPLE, BESIDE-MR, debiased IVW) and mediation analysis to assess the causal impact of DPP4 at the mRNA level on CVD and the direct effect of DPP4 at the mRNA level on CVD, not mediated by diabetes. The causality of DPP4 inhibition on CVD was also evaluated. <b>Results:</b> MR-RAPS suggested a potential causal relationship between increased DPP4 at the mRNA levels and HF (0.031 [95% CI, 0.06-0.56; <i>p</i>=0.014]). However, there was limited evidence that increased DPP4 levels affect AF, MI, or stroke. Other analyses corroborated these findings. Mediation analysis indicated a direct effect of DPP4 at the mRNA level on HF, while debiased IVW showed limited evidence for a causal effect of DPP4 inhibition on CVDs, possibly due to low statistical power. <b>Conclusions:</b> Mendelian randomization analyses support the cardiovascular safety of DPP4 inhibitors in managing type 2 diabetes, with little evidence for DPP4-mediated cardiovascular harm, reinforcing their appropriateness for clinical use in European populations. Additionally, if DPP4 inhibition affects cardiovascular outcomes, it may not do so through glycemic control, such as HbA1c reduction.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"2357272"},"PeriodicalIF":2.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening for the Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Among Patients With Prediabetes and Type 2 Diabetes: A Comparison of Three Screening Systems.","authors":"Ruba H Alhabahbeh, Ala'eddien N Obeidat, Dunia S Jaber, Mohammed M AlKhaldi, Leen K Ghanem, Ahmad A Tubasi, Zaina N Obeidat, Hussam H Alhawari","doi":"10.1155/ije/6676114","DOIUrl":"10.1155/ije/6676114","url":null,"abstract":"<p><p><b>Purpose:</b> To screen for the prevalence and severity of nonalcoholic fatty liver disease (NAFLD) and degree of liver fibrosis in patients with prediabetes and Type 2 diabetes. Additionally, we sought to compare the results obtained from different screening systems. <b>Methods:</b> We screened 254 patients for NAFLD using three systems: Fatty Liver Index (FLI), Fibrosis 4 (FIB-4) Index, and NAFLD Fibrosis Score (NFS). About two-thirds were females (63%). The mean age was 59.15 ± 10.09 years, and mean BMI was 34.14 ± 6.60 kg/m². Among participants, 85.5% had Type 2 diabetes and 14.5% had prediabetes. Additionally, 81.1% were on metformin, and 39.6% were on insulin. <b>Results:</b> Probable steatosis (NAFLD) prevalence was 77.0% (FLI score) in our cohort. Moderate to advanced liver fibrosis was 12.6% (NFS score) and 20.7% (FIB-4 score). Significant discrepancies were noted: FIB-4 identified 21.6% of patients with moderate to severe fibrosis, which FLI did not recognize as NAFLD. FIB-4 also identified 26 patients with moderate to severe fibrosis that NFS missed. The FIB-4 and FLI score discrepancy was more common in females (10.2% vs. 1.7%, <i>p</i> = 0.046) and in patients with diabetes compared to prediabetes (21.7% vs. 4.5%, <i>p</i> = 0.003). The FIB-4 and NFS score discrepancy was more common in patients with higher BMI (38.38 ± 7.78 vs. 33.59 ± 6.82, <i>p</i> < 0.001) and in those with prediabetes compared to diabetes (34.8% vs. 12.8%, <i>p</i> = 0.008). <b>Conclusion:</b> The study found a high prevalence (77%) of NAFLD in individuals with prediabetes and diabetes. About 20% had moderate to advanced liver fibrosis. NAFLD prevalence and severity varied significantly across three scoring systems. Key factors for refining screening strategies include patient sex, BMI, and the level of insulin resistance.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"6676114"},"PeriodicalIF":2.3,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12393924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Consistency of <i>CDC73</i> Mutation and Parafibromin Staining Loss in Parathyroid Neoplasm: A Systematic Review.","authors":"Jinheng Xiao, Sen Yang, Qingyuan Zheng, Tianqi Chen, Ya Hu","doi":"10.1155/ije/1905585","DOIUrl":"10.1155/ije/1905585","url":null,"abstract":"<p><p><b>Background:</b> Primary hyperparathyroidism (pHPT) caused by parathyroid neoplasm is a common endocrine disorder. Nuclear staining loss of parafibromin, encoded by the <i>CDC73</i> gene, has been shown to be closely related to parathyroid malignancy and poor prognosis. Although previous studies have found that parafibromin staining loss is not always consistent with <i>CDC73</i> mutation, the reasons are still unknown. <b>Methods:</b> Published studies from the PubMed database were searched using the terms \"parafibromin,\" \"<i>CDC73</i>,\" \"<i>HRPT2</i>,\" and \"parathyroid\" to identify eligible studies. Among the included studies, <i>CDC73</i> mutation and parafibromin immunohistochemical (IHC) results for patients with parathyroid neoplasms were reviewed, and possible reasons for the inconsistency between the parafibromin staining loss and <i>CDC73</i> mutation were explored. This systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 analysis protocol. <b>Results:</b> A total of 299 patients from 32 studies were included in the present review. Inconsistency and consistency between parafibromin staining and <i>CDC73</i>status was observed in 19.40% and 80.60% of patients. Patients in the inconsistency group showed higher level of serum calcium (<i>p</i> = 0.026). Significant difference in the inconsistency rate was found between PC (25.15%) and non-PC group (12.50%) (<i>p</i> < 0.001), and NGS (8.51%) and non-NGS group (21.43%) (<i>p</i> = 0.006) in multivariate analysis. <b>Conclusion:</b> The main reasons for the inconsistency were attributed to the pathological type and sequencing method. More inconsistent results were detected in the PC group and the non-NGS group.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"1905585"},"PeriodicalIF":2.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Astaxanthin Modulates Inflammation in Type 2 Diabetes via Regulation of microRNAs, Lysophosphatidylcholine, and α-Hydroxybutyrate.","authors":"Ali Sharifi-Rigi, Fatemeh Zal, Mohammad-Hossein Aarabi, Mehdi Dehghani, Nikoo Roustaei Rad, Sana Taghiyar","doi":"10.1155/ije/5878361","DOIUrl":"10.1155/ije/5878361","url":null,"abstract":"<p><p>Astaxanthin is a carotenoid compound that has several beneficial qualities, including antioxidant, anti-inflammatory, antiapoptotic, and antidiabetic effects. This study examined the effects of astaxanthin supplementation on inflammation-related microRNAs, lysophosphatidylcholine, and α-hydroxybutyrate in individuals with Type 2 diabetes. Fifty people with Type 2 diabetes volunteered in a placebo-controlled, randomized, double-blind clinical trial. Subjects were randomly determined to consume either 10 mg of astaxanthin (<i>n</i> = 25) or a placebo (<i>n</i> = 25) for 12 weeks. Quantitative real-time PCR was employed to assess the expression of inflammation-related microRNAs in peripheral blood mononuclear cells both before and after the intervention, and we employed ELISA to ascertain the serum levels of lysophosphatidylcholine and α-hydroxybutyrate. After 12 weeks of supplementation, in comparison with placebo, astaxanthin supplementation resulted in a noteworthy decrease (<i>p</i> < 0.05) in hsa-miR-21, hsa-miR-34a, and hsa-miR-155 expression. In addition, astaxanthin supplementation substantially decreased (<i>p</i> < 0.05) the levels of lysophosphatidylcholine and α-hydroxybutyrate compared with the placebo. These changes suggest that astaxanthin may contribute to the modulation of inflammatory processes and the enhancement of metabolic homeostasis. Moreover, relative to the placebo, astaxanthin supplementation considerably diminished serum plasma glucose, HbA1c, lipid profile, and albumin-to-creatinine ratio levels. In conclusion, the current investigation indicates that astaxanthin supplementation at a dosage of 10 mg per day might be a useful strategy for ameliorating inflammation-related diabetic complications and insulin resistance in Type 2 diabetes patients. Considering the potential role of microRNAs in regulating inflammation and metabolic dysfunction in Type 2 diabetes, these findings suggest that astaxanthin supplementation may modulate inflammation-related microRNAs and metabolic markers, potentially contributing to the management of inflammatory processes and metabolic dysregulation in Type 2 diabetes. <b>Trial Registration:</b> Iranian Registry of Clinical Trials (IRCT): IRCT20190305042939N1.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"5878361"},"PeriodicalIF":2.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between PNPLA3 Inhibition and Gout: A Drug Target Mendelian Randomization Study.","authors":"Chen Wang, Pei Guo, Xiang Liu, Xingxing Xu, Li Zou, Shi Meng, Qing Guo, Qiang Wen, Chuang Yang","doi":"10.1155/ije/6664846","DOIUrl":"10.1155/ije/6664846","url":null,"abstract":"<p><p><b>Aims:</b> Patatin-like phospholipase domain-containing protein 3 (PNPLA3) plays a crucial role in metabolic dysfunction-related steatotic liver disease. ARO-PNPLA3 is a therapeutic agent designed to target PNPLA3, but its long-term effects remain uncertain. The objective of this study was to ascertain the impact of PNPLA3 inhibition on the risk of gout through Mendelian randomization. <b>Methods:</b> Mendelian randomization analysis was conducted by choosing single nucleotide polymorphisms (SNPs) in proximity to the PNPLA3 gene, which were significantly associated with the percentage of hepatic fat, to represent PNPLA3 suppression. Nonalcoholic fatty liver disease and hepatic fibrosis served as positive controls, while urate and gout were the outcomes. <b>Results:</b> Genetically predicted PNPLA3 inhibition significantly increased the risk of gout (OR: 1.83, 95% CI: 1.49 to 2.26, <i>p</i> = 1.44 × 10^-8), idiopathic gout (OR: 2.42, 95% CI: 1.60 to 3.65, <i>p</i> = 2.81 × 10^-5) and urate (OR: 1.12, 95% CI: 1.01 to 1.23, <i>p</i> = 2.56 × 10^-2), but not with gout due to impairment of renal function (OR: 1.25, 95% CI: 0.37 to 4.22, <i>p</i> = 7.23 × 10^-1). <b>Conclusions:</b> This study found that PNPLA3 inhibition increased the risk of high urate level and gout. In addition, PNPLA3 inhibition also increased triglyceride (TG) levels, which partially mediate the relationship between PNPLA3 inhibition and gout. <b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT04844450.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"6664846"},"PeriodicalIF":2.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baihu Jia Renshen Decoction Improves Type 1 Diabetic Rats by Modulating Metabolic Profile.","authors":"Shufang Chu, Deliang Liu, Hengxia Zhao, Ling Liu, Juntong Li, Gaoxiang Wang, Xuemei Liu, Huilin Li","doi":"10.1155/ije/2139427","DOIUrl":"10.1155/ije/2139427","url":null,"abstract":"<p><p><b>Background:</b> Baihu Jia Renshen Decoction (BJRD) applied to diabetes mellitus (DM). We explored the metabolic regulatory pathways and mechanisms of BJRD in Type 1 DM (T1DM). <b>Methods:</b> T1DM rat model was established with STZ induction and then continuously treated with insulin and different concentrations of BJRD for 2 weeks. The therapeutic effect of BJRD was evaluated by detecting the levels of fasting blood glucose and insulin in the blood and observing the ultrastructure of pancreatic tissues by transmission electron microscopy and immunofluorescent staining. Metabolomics analysis on rat serum was performed. <b>Results:</b> Compared with the diabetes model (DC) group, the high-concentration BJRD treatment (BJRD-H) group reduced fasting blood glucose, increased insulin levels, and increased the quantity of β-cells in the pancreatic tissues in rats. And rat pancreatic islet β-cells in the DC group had lost their nuclear membranes, had abnormal mitochondrial morphology, and had significantly reduced secretory granules, whereas rat pancreatic islet β-cells in the BJRD-H group had moderately increased secretory granules, and the structure of the nucleus was apparently normal. Moreover, the metabolic profile expression pattern of rats in the BJRD-H group was closer to that of normal rats, suggesting that a high concentration of BJRD combined with insulin treatment was more effective. And differentially expressed metabolites were predominantly enriched in amino acid metabolism, including amino acids, glycine, serine, and threonine metabolism. <b>Conclusion:</b> BJRD facilitated the therapeutic effect of insulin in T1DM rats and resulted in a significant improvement in their metabolic profiles, expanding the application of traditional Chinese medicine's alternative therapies in T1DM.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"2139427"},"PeriodicalIF":2.3,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to \"Bidirectional Mendelian Randomization Analysis for Vitamin D and Thyroid Peroxidase Antibody\".","authors":"","doi":"10.1155/ije/9878270","DOIUrl":"10.1155/ije/9878270","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1155/2022/2260388.].</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"9878270"},"PeriodicalIF":2.3,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Bone Turnover Markers in Adults with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis\".","authors":"","doi":"10.1155/ije/9836309","DOIUrl":"10.1155/ije/9836309","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1155/2023/9957194.].</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"9836309"},"PeriodicalIF":2.3,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}